Holen Sie sich die Stockscreener-App
1.42
3.62%
0.04
Schlusskurs vom Vortag:
$1.38
Offen:
$1.38
24-Stunden-Volumen:
1.64M
Relative Volume:
0.23
Marktkapitalisierung:
$315.27M
Einnahmen:
$2.04M
Nettoeinkommen (Verlust:
$-43.21M
KGV:
-6.8699
EPS:
-0.2067
Netto-Cashflow:
$-105.93M
1W Leistung:
+2.88%
1M Leistung:
+34.91%
6M Leistung:
+12.60%
1J Leistung:
-44.14%
1-Tages-Spanne:
$1.37
$1.50
1-Wochen-Bereich:
$1.33
$1.525
52-Wochen-Spanne:
$0.5469
$2.82
Humacyte Inc Stock (HUMA) Company Profile
Firmenname
Humacyte Inc
Sektor
Branche
Telefon
919-313-9633
Adresse
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
1.42 | 306.39M | 2.04M | -43.21M | -105.93M | -0.2067 |
VRTX
Vertex Pharmaceuticals Inc
|
443.64 | 112.43B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
616.24 | 64.09B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
882.15 | 54.88B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.81 | 39.01B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
148.35 | 31.57B | 742.00K | -1.37B | -1.07B | -7.0731 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-27 | Eingeleitet | Barclays | Overweight |
| 2025-05-14 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-12-20 | Bestätigt | H.C. Wainwright | Buy |
| 2023-12-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-14 | Hochstufung | Piper Sandler | Underweight → Neutral |
| 2023-06-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-05-16 | Herabstufung | Piper Sandler | Overweight → Underweight |
| 2021-10-29 | Eingeleitet | Cowen | Outperform |
| 2021-09-24 | Eingeleitet | Oppenheimer | Outperform |
| 2021-09-22 | Eingeleitet | BTIG Research | Buy |
| 2021-09-16 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Humacyte Inc Aktie (HUMA) Neueste Nachrichten
HUMA: All proposals, including director elections and share increase, passed with strong support - TradingView
HUMA Reiterates by BTIG -- Price Target Maintained at $2.00 - GuruFocus
Humacyte, Inc. Files Form 8-K with SEC: Company Details, Stock Information, and Regulatory Disclosures - Minichart
Humacyte Regains Nasdaq Compliance With Minimum Bid Price - TipRanks
Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - Lelezard
Humacyte regains Nasdaq $1.00 bid-price compliance after May deficiency - TradingView
Humacyte (NASDAQ: HUMA) back in line with Nasdaq $1.00 bid rule - Stock Titan
HUMA Technical Analysis | Trend, Signals & Chart Patterns | HUMACYTE INC (NASDAQ:HUMA) - ChartMill
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - TMX Newsfile
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - TMX Newsfile
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - TMX Newsfile
Benchmark raises Humacyte stock price target on dialysis launch hopes By Investing.com - Investing.com South Africa
Benchmark Co. Maintains Humacyte(HUMA.US) With Buy Rating, Raises Target Price to $2 - Moomoo
HUMA Maintained by Benchmark -- Price Target Raised to $2.00 - GuruFocus
Humacyte (HUMA) Q1 2025 Earnings Transcript - The Globe and Mail
Benchmark raises Humacyte stock price target on dialysis launch hopes - Investing.com
Humacyte (HUMA) Is Up 23.8% After Long-Term Self-Repair Dialysis DataHas The Bull Case Changed? - Yahoo Finance
Humacyte (HUMA) Is Up 23.8% After New ATEV Self‑Repair Data And Phase 3 Timeline Update - Sahm
Humacyte, Inc. (HUMA) reports Q1 loss, misses revenue estimates - MSN
Humacyte, Inc. (HUMA) stock sinks as market gains: Here's why - MSN
Humacyte appoints Todd Rasmussen as chief surgical officer By Investing.com - Investing.com Nigeria
Wall Street bulls look optimistic about Humacyte, Inc. (HUMA): Should you buy? - MSN
Wall Street Bulls Look Optimistic About Humacyte, Inc. (HUMA): Should You Buy? - Yahoo Finance
H.C. Wainwright Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $3 - Moomoo
Humacyte Inc. (HUMA) Gains 3.6% as Stock Approaches Key Resistance LevelMA Crossover - thelegaladvocate.com
HUMA Reiterates by HC Wainwright & Co. -- Price Target Maintained at $3.00 - GuruFocus
Humacyte Price Target Maintained With a $3.00/Share by HC Wainwright & Co. - Moomoo
Humacyte presents dialysis access vessel research at VASA meeting By Investing.com - Investing.com Nigeria
Humacyte presents dialysis access vessel research at VASA meeting - Investing.com
Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access - The Manila Times
Dialysis graft that self-repairs despite hundreds of needle sticks - Stock Titan
Humacyte secures $1.5M Saudi order – why did HUMA stock crash to record low today? - MSN
HUMA Q1 2026 Earnings: Narrowing Losses Drive Positive Surprise as Stock Gains 11%Banking Earnings Report - thelegaladvocate.com
Humacyte (HUMA) director Kathleen Sebelius purchases 56,818 shares at $0.88 - Stock Titan
Humacyte (HUMA) director adds 11,000 shares at about $0.89 - Stock Titan
Humacyte (HUMA) CFO executes 45,887-share sell-to-cover trade for RSU taxes - Stock Titan
Humacyte (HUMA) CMO executes 45,887-share tax sell-to-cover under 10b5-1 plan - Stock Titan
Humacyte’s Symvess added to VA hospital contract system - Investing.com UK
Humacyte’s Symvess added to VA hospital contract system By Investing.com - Investing.com South Africa
VA hospitals to get easier access to Humacyte Symvess product - Stock Titan
Why Humacyte, Inc. (HUMA) Price Target Was Raised Despite Early-Stage Commercialization - Insider Monkey
[144] Humacyte, Inc. SEC Filing - Stock Titan
Number of shareholders of Humacyte, Inc. – NASDAQ:HUMA - TradingView
Finanzdaten der Humacyte Inc-Aktie (HUMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.62%
1.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):